Moscow: The COVID-19 vaccine, Sputnik V, approved by Russia last month, has been shown to elicit antibody response with no serious adverse events in small human trials, according to preliminary results published in The Lancet journal on Friday.
Results from early-phase non-randomised vaccine trials in a total of 76 people show that two formulations of the vaccine have a good safety profile detected over 42 days, and induce antibody responses in all participants within 21 days.
Secondary outcomes from the trial suggest the vaccines also produce a T cell response within 28 days, the researchers said.
The findings are based on two small phase trials lasting 42 days -- one studying a frozen formulation of the vaccine, and another involving a lyophilised (freeze-dried) formulation of the vaccine, they said.
The frozen formulation is envisaged for large-scale use in existing global supply chains for vaccines, while the freeze-dried formulation was developed for hard-to-reach regions as it is more stable and can be stored at 2-8 degrees Celsius, the researchers said.
The two-part vaccine includes recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S), which have been modified to express the SARS-CoV-2 spike protein.
The adenoviruses, which usually cause the common cold, are also weakened so that they cannot replicate in human cells and cannot cause disease, according to the researchers.
These vaccines aim to stimulate both arms of the immune system -- antibody and T cell responses -- so they attack the virus when it is circulating in the body, and also attack cells infected by SARS-CoV-2.
"When adenovirus vaccines enter people's cells, they deliver the SARS-CoV-2 spike protein genetic code, which causes cells to produce the spike protein," said study lead author Denis Logunov, from Gamaleya National Research Centre for Epidemiology and Microbiology, Russia.
"This helps teach the immune system to recognise and attack the SARS-CoV-2 virus. To form a powerful immune response against SARS-CoV-2, it is important that a booster vaccination is provided," Logunov said.
However, Logunov said, booster vaccinations that use the same adenovirus vector might not produce an effective response.
He said this is because the immune system may recognise and attack the vector, adding this would block the vaccine from entering people's cells and teaching the body to recognise and attack SARS-CoV-2.
"For our vaccine, we use two different adenovirus vectors in a bid to avoid the immune system becoming immune to the vector," Logunov added.
The trials took place in two hospitals in Russia, and were open-label and non-randomised, meaning that participants knew that they were receiving the vaccine and were not assigned by chance to different treatment groups.
The trials involved healthy adults aged 18-60 years, who self-isolated as soon as they were registered, and remained in hospital for the first 28 days of the trial from when they were first vaccinated.
In the phase 1 of each trial, participants received one component of the two-part vaccine -- four groups of nine participants were given the frozen or freeze-dried rAd26-S or rAd5-S component.
In the phase 2, which began no earlier than five days after the phase 1 trial began, participants received the full two-part vaccine -- they received a prime vaccination with the rAd26-S component on day 0, followed by a booster vaccination with rAd5-S component on day 21.
There were 20 participants each in the frozen and freeze-dried vaccine groups, the Lancet study noted.
To compare post-vaccination immunity with natural immunity formed by infection with SARS-CoV-2, the authors obtained convalescent plasma from 4,817 people who had recovered from mild or moderate COVID-19, they said.
Both vaccine formulations were safe over the 42-day study period and well tolerated, according to the study.
The most common adverse events were pain at the injection site, hyperthermia, headache, asthenia (weakness or lack of energy), and muscle and joint pain.
The authors note that these adverse effects are also seen with other vaccines, particularly those based on recombinant viral vectors.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
New Delhi (PTI): The New Year evening was streaked with blood with three almost back-to-back stabbings leaving an equal number of people dead in Delhi.
Bihari Lal, 50, was allegedly stabbed in an attack by a group of juveniles when he asked them to stop shouting and playing loud music in northwest Delhi's Lal Bagh area.
A tailor by profession, Bihari Lal had just returned home Thursday evening from his job in Shastri Nagar, when he was faced with a raucous mob of revellers, whom he chastised for making noise.
"This led to a heated exchange, during which one of the juveniles stabbed Lal," a police officer said, adding that one of the boys kicked the victim several times during the fight.
Bihari Lal was rushed to Babu Jagjivan Ram Memorial Hospital, where doctors declared him dead.
Police apprehended a juvenile in connection with the killing and seized the weapon of the crime. A hunt for the rest involved in the fight is on.
An FIR was registered at the Adarsh Nagar Police Station, and investigators are examining eyewitness accounts and CCTV footage from the area.
Bihari Lal's family and neighbours alleged that the group was notorious for creating disturbance in the area.
"He had just returned from duty and was parking his cycle when they came and started abusing everyone, throwing buckets, boxes and people's belongings. Bihari Lal only told them not to use abusive language and shout, as there were women and children around. That was all he said," Dimple, a neighbour, recounted.
Pushpa, a relative, alleged that the group had been terrorising residents for some time. "They keep throwing bottles, stones and sticks, and nobody does anything. We complained earlier, but no action was taken. The police never did anything," she said.
Pushpa said four boys were involved in the attack and "they stabbed him three times."
Hours later, in outer Delhi's Mangolpuri, an e-rickshaw driver, Vikas, was stabbed in a fight.
According to police, Vikas and his friend Sandeep, a daily-wage labourer, both aged 20, were sitting together when a group of youths started a fight with them.
"During the altercation, one of the accused stabbed Vikas, causing fatal injuries. Sandeep also suffered a minor lacerated wound," an officer said.
Both were taken to a nearby hospital, where Vikas was declared dead.
Preliminary investigation revealed that the victims and the attackers had bad blood, police said.
All six accused, four of them underage, involved in the stabbing were apprehended, police said.
The same evening, a 15-year-old boy was stabbed to death in nearby Sultanpuri.
Around 11.30 pm, police were informed that a group of men had attacked a minor with a knife.
"A police team rushed to the spot and found the injured boy lying on the road with multiple stab wounds," an officer said.
The victim, whose identity was not revealed by the police, was rushed to a hospital, where he was declared dead.
Vikram, a man aged about 30 with a history of crime, was arrested for allegedly killing the boy.
During interrogation, Vikram, who police said has six criminal convictions, revealed that two more men were with him at the time of the stabbing. A search for them has been launched.
The boy's mother said her son had been threatened several times before by the attackers, but police took no action.
"My son had gone out only to get some juice when a few people started abusing him, and a fight broke out. I ran downstairs from my sister's house and begged them not to harm my son. Instead, they took out a knife and attacked me. I somehow ran into a shop, where I saw my son being stabbed in front of my eyes," the boy's mother, Bali, said.
She said that the accused had earlier also entered her house armed with weapons. "I informed the police, but no action was taken."
The boy was her only son.
The motive of the killing is yet to be ascertained by the police.
